---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-006382"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:47:11.942581+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q1 revenue $3.8M, up 38% pro forma; net loss $3.9M

## Summary
- Revenue $3.8M (74% gross margin) vs $14K in Q1 2021; up 38% over combined Zomedica+PulseVet $2.7M.
- PulseVet revenue $3.7M (+36% vs standalone Q1 2021); small animal unit sales 30 (+500% YoY).
- TRUFORMA product revenue $57K (+307% vs $14K); launched endogenous ACTH assay in April 2022.
- Cash $192.3M at quarter end; net loss $3.9M ($0.004/share) vs $36.0M loss in Q1 2021.
- SG&A $6.7M (+91% YoY) driven by share-based comp and sales force expansion; R&D $351K.

## SEC filing metadata
- accession: 0001654954-22-006382
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495422006382/0001654954-22-006382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495422006382/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-006382
- JSON: https://secwatch.observer/filing/0001654954-22-006382.json
- Plain text: https://secwatch.observer/filing/0001654954-22-006382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.